Clinical and microbiological features and outcomes of mucormycosis in critically ill patients

被引:11
|
作者
Rothe, Kathrin [1 ]
Braitsch, Krischan [2 ]
Okrojek, Rainer [3 ]
Heim, Markus [4 ]
Rasch, Sebastian [5 ]
Verbeek, Mareike [2 ]
Schmid, Roland M. [5 ]
Busch, Dirk H. [1 ,6 ]
Lahmer, Tobias [5 ]
机构
[1] Tech Univ Munich, Sch Med, Inst Med Microbiol Immunol & Hyg, Munich, Germany
[2] Tech Univ Munich, Sch Med, Dept Internal Med 3, Munich, Germany
[3] Tech Univ Munich, Sch Med, Dept Internal Med 1, Munich, Germany
[4] Tech Univ Munich, Sch Med, Dept Anaesthesiol & Intens Care Med, Munich, Germany
[5] Tech Univ Munich, Sch Med, Dept Internal Med 2, Munich, Germany
[6] German Ctr Infect Res, Partner Site Munich, Munich, Germany
关键词
Mucormycosis; Isavuconazole; Intensive care treatment; Combination antifungal therapy; INVASIVE ASPERGILLOSIS; FUNGAL-INFECTIONS; ISAVUCONAZOLE; DIAGNOSIS;
D O I
10.1016/j.ijid.2021.06.066
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction: Mucormycosis is a rare invasive fungal infection with high mortality in patients with severe underlying predisposing factors causing immunosuppression. The exact incidence of mucormycosis and the optimal therapeutic approach is difficult to determine, especially in severe cases, due to the rarity of the disease. The new second-generation triazole isavuconazole provides an alternative treatment option which may represent a potential benefit in severe cases. Materials and methods: A retrospective case series was conducted of patients with a positive laboratory culture for Mucorales and consistent clinical findings who required intensive care treatment. Patient char-acteristics including demographics, comorbidities, microbiological analysis, specific antifungal therapy and clinical outcome were analysed. Results: Fifteen critically ill patients with Mucorales detected between 2016 and 2019 were included in this study; the crude mortality rate was 100%. At the time of diagnosis of mucormycosis, 80% of sub-jects had relevant medical immunosuppression and 53.3% of subjects had neutropenia. Manifestation of mucormycosis was pulmonary in 53.3% of subjects, rhino-orbital in 20% of subjects and disseminated in 26.7% of subjects. Notably, 40% of all patients had received antifungal prophylaxis prior to mucormyco-sis, mainly with posaconazole due to underlying haematological malignancy, thus possibly representing break-through infections. Antifungal therapy for invasive mucormycosis was administered in 80% of sub-jects for a median duration of 16 days. Conclusion: In this retrospective cohort analysis of intensive care patients, the prognosis of mucormycosis was extremely poor. An aggressive strategy for diagnosis and treatment is essential for intensive care patients with mucormycosis. There is a need for further research to determine if combination therapy in higher dosages or prompt surgery is beneficial in severe critically ill patients. (c) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:142 / 147
页数:6
相关论文
共 50 条
  • [1] CRITICALLY ILL PATIENTS WITH SUBSTANCE USE DISORDER: A REPORT OF CLINICAL FEATURES AND OUTCOMES
    Bandak, Ghassan
    Abouzid, Mahmoud
    Mahdi, Ahmed
    Mansoor, Kanaan
    Sakhuja, Ankit
    Gress, Todd
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 220 - 220
  • [2] Clinical features and outcomes of critically ill patients with Elizabethkingia meningoseptica: an emerging pathogen
    Umair, Abdullah
    Nasir, Nosheen
    ACUTE AND CRITICAL CARE, 2021, 36 (03) : 256 - 261
  • [3] Neurological complications of HIV infection in critically ill patients: Clinical features and outcomes
    Sonneville, R.
    Ferrand, H.
    Tubach, F.
    Roy, C.
    Bouadma, L.
    Klein, I. F.
    Foucrier, A.
    Regnier, B.
    Mourvillier, B.
    Wolff, M.
    JOURNAL OF INFECTION, 2011, 62 (04) : 301 - 308
  • [4] CLINICAL FEATURES AND OUTCOMES OF CRITICALLY ILL ELDERLY PATIENTS WITH COVID-19 INFECTION
    Mahdi, Ahmed
    Abouzid, Mahmoud
    Raru, Yonas
    Kumar, Anup
    Aguilar, Rodrigo
    Shweihat, Yousef
    Bandak, Ghassan
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 57 - 57
  • [5] MUSCLE ATROPHY AND CLINICAL OUTCOMES IN CRITICALLY ILL PATIENTS
    Lin, A.
    Gonzalez-Cuyar, L.
    Bunnell, A.
    Hough, C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2016, 64 (01) : 191 - 191
  • [6] CLINICAL FEATURES AND OUTCOMES OF CRITICALLY ILL, PATIENTS WITH SHIGATOXIN-INDUCED HEMOLYTIC UREMIC SYNDROME
    Braune, S.
    Wichmann, D.
    von Heinz, M.
    Nierhaus, A.
    Becker, H.
    Meyer, G.
    Mueller-Schulz, M.
    Fricke, J.
    de Weerth, A.
    Hoepker, W.
    Fiehler, J.
    Magnus, T.
    Gerloff, C.
    Panzer, U.
    Stahl, R.
    Kluge, S.
    INTENSIVE CARE MEDICINE, 2012, 38 : S240 - S240
  • [7] Clinical features of critically ill patients with invasive fungal infection
    Borges-Sa, Marcio
    Aranda-Perez, Maria
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2012, 29 (02): : 102 - 107
  • [8] Pulmonary mucormycosis: clinical features and outcomes
    Erica Lin
    Teng Moua
    Andrew H. Limper
    Infection, 2017, 45 : 443 - 448
  • [9] Pulmonary mucormycosis: clinical features and outcomes
    Lin, Erica
    Moua, Teng
    Limper, Andrew H.
    INFECTION, 2017, 45 (04) : 443 - 448
  • [10] Lung Microbiota Predict Clinical Outcomes in Critically Ill Patients
    Dickson, Robert P.
    Schultz, Marcus J.
    van der Poll, Tom
    Schouten, Laura R.
    Falkowski, Nicole R.
    Luth, Jenna E.
    Sjoding, Michael W.
    Brown, Christopher A.
    Chanderraj, Rishi
    Huffnagle, Gary B.
    Bos, Lieuwe D. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (05) : 555 - 563